Related Experiment Video
Updated: Sep 2, 2025
Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
Published on: September 27, 2024
Cardiovascular markers and COVID-19
El-Houcine Sebbar1,2, Mohammed Choukri1,2
1Faculty of Medicine and Pharmacy of Oujda, Mohammed First University, PB 724, Oujda 60000, Morocco.
Insights
Biomarkers like troponin and d-dimer indicate cardiac injury in COVID-19 patients. Elevated levels predict severe outcomes and mortality, highlighting their importance in disease management.
Area of Science:
- Cardiology
- Infectious Diseases
- Biomarkers
Background:
- COVID-19 presents with varied clinical profiles and incompletely understood pathogenesis.
- Cardiovascular complications are frequent, including acute cardiac injury, myocardial infarction, myocarditis, heart failure, and thromboembolism.
- Elevated cardiac biomarkers suggest myocardial damage as a key factor in severe COVID-19.
Purpose of the Study:
- To emphasize the predictive value of cardiac biomarkers for cardiovascular complications in COVID-19.
- To explore the role of these biomarkers in the disease's progression and patient outcomes.
Main Methods:
- Analysis of biomarker levels (BNP/NT-proBNP, troponin, d-dimer) in COVID-19 patients.
- Correlation of biomarker levels with clinical presentation and disease severity.
- Assessment of biomarker association with adverse cardiovascular events and mortality.
Main Results:
- Significant elevations in BNP/NT-proBNP, troponin, and d-dimer were observed in a substantial number of patients.
- Higher levels of these biomarkers correlated with increased risk of adverse outcomes, including mortality.
- Myocardial damage, indicated by these markers, appears to be a critical pathogenic mechanism.
Conclusions:
- Cardiac biomarkers are crucial for predicting cardiovascular complications in COVID-19.
- Monitoring these markers aids in risk stratification and understanding disease evolution.
- These biomarkers play a significant role in assessing the prognosis of COVID-19 patients.
Abstract:
COVID-19 is an emerging viral disease with incompletely elucidated pathogenesis, a heterogeneous clinical profile, and significant interindividual variability. The major cardiovascular complications of COVID-19 include acute cardiac injury, acute myocardial infarction (AMI), myocarditis, arrhythmia, heart failure, and venous thromboembolism (VTE)/pulmonary embolism (PE). Elevated BNP /NT-proBNP, troponin and d-dimer levels has been found in a significant proportion of patients since the first data analysis, suggesting that myocardial damage is a likely pathogenic mechanism contributing to severe disease and mortality. The level of these markers is now associated with a risk of adverse outcome, namely mortality. The aim of our study is to highlight the importance of these biomarkers for the prediction of cardiovascular complications and their potential role in the evolution of COVID-19.
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:30Coronary Artery Disease I: Introduction
01:27Myocarditis II: Clinical Features and Diagnostic Tests
01:30Coronary Artery Disease III: Clinical Manifestations